Long-term safety and effectiveness of linagliptin as add-on therapy in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance. Issue 3 (4th March 2021)

• Record Type: Journal Article
• Authors: Ito, Tomohiro; Naito, Yusuke; Shimmoto, Naoki; Ochiai, Kaori; Hayashi, Naoyuki; Okamura, Tomoo
• Is Part Of: Expert opinion on drug safety. Volume 20:Issue 3(2021)
• Page Start: 363
• Page End: 372
• Publication Date: 2021-03-04
• Subjects: Diabetes mellitus -- type 2 -- linagliptin -- product surveillance -- postmarketing; Drugs -- Side effects -- Periodicals; Drugs -- Toxicology -- Periodicals; Chemotherapy -- Periodicals; 615.704
• DOI: 10.1080/14740338.2021.1859477
• Languages: English
• ISSNs: 1474-0338

Abstract

ABSTRACT: Background: We investigated the long-term safety and effectiveness of linagliptin in Japanese type 2 diabetes (T2D) patients starting linagliptin add-on therapy in routine clinical practice. Research design and methods: This 3-year prospective, observational, post-marketing surveillance (PMS) was conducted in Japanese patients starting linagliptin add-on therapy. The primary outcome was the incidence of adverse drug reactions (ADRs). The secondary outcome was the change from baseline in HbA1c. Results: The safety analysis set comprised of 3, 372 patients. Mean ± standard deviation (SD) age was 66.5 ± 12.4 years. Most patients (63.2%) received linagliptin in combination with another antidiabetic drug, most commonly a sulfonylurea (38.6%). The incidence of ADRs was 11.39%; the most common ADRs according to MedDRA preferred terms were diabetes mellitus (1.25%), hypertension (0.83%), and hypoglycemia (0.80%). In the effectiveness analysis set (n = 3, 029), mean ± SD HbA1c was 7.76 ± 1.37% at baseline and 7.26 ± 1.19% at last observation; mean change from baseline to last observation was – 0.49 ± 1.33%; sustained reductions in HbA1c were observed. These results were consistent across patient subgroups. Conclusions: In this PMS, linagliptin add-on therapy for Japanese T2D patients had a safety profile consistent with its known profile and HbA1c reductions over 3 years were observed. ClinicalTrials.gov: NCT01904383